Malignant Pleural Mesothelioma: Pleural Decortication and Multimodal Therapy

ByHolly Zink
Malignant Pleural Mesothelioma: Pleural Decortication and Multimodal Therapy

Malignant pleural mesothelioma is a severe cancer caused by asbestos exposure. It impacts the lungs’ lining. Treating it is tough, as it’s aggressive and often diagnosed late.

However, new surgical and therapy methods are offering hope. A recent article looks at pleural decortication, a crucial surgery, and how multimodal therapy helps.

What is Pleural Decortication?

Pleural decortication is a surgery that removes tumors and tough lung and chest wall tissue. It’s crucial in EPD, which treats mesothelioma.

First, the surgeon removes the tumor and pleura. This allows the lung to expand fully. The surgery is methodical and exact. It ensures full tumor removal with minimal damage. Skilled thoracic surgeons in specialized centers usually perform this complex surgery.

Hyperthermic Intrathoracic Chemotherapy (HITHOC)

After removing the tumor, doctors use HITHOC. They heat chemotherapy and circulate it in the chest. This targets any remaining cancer cells.

Heating the solution boosts its cancer-killing power. Unlike regular chemotherapy, HITHOC sends high drug doses directly to the tumor. This reduces overall side effects. The procedure takes 60-90 minutes.

Multimodal Therapy: A Comprehensive Approach

Multimodal therapy combines treatments for better outcomes in pleural mesothelioma patients. It includes surgery, chemotherapy, and radiation.

Pleural decortication and EPD surgeries aim to remove as much tumor as possible. Systemic chemotherapy or HITHOC then targets any remaining cancer cells. This prevents the cancer from coming back. Post-surgery radiation can also be used. It kills any leftover cancer cells and lowers the risk of a comeback.

Benefits of Multimodal Therapy:

Multimodal therapy offers several benefits. Firstly, it boosts survival. Studies prove it extends survival in some patients with malignant pleural mesothelioma, especially those with the epithelioid subtype.

Also, it cuts recurrence. By using various treatments, it tackles cancer from different sides, making recurrence less likely. Moreover, it provides tailored treatment. Multimodal therapy allows for a personalized approach based on the patient’s condition and disease stage.

Case Study: Multimodal Therapy in Action

A recent case study showed success in treating epithelioid mesothelioma. It used an extended pleurectomy/decortication with HITHOC. The patient, treated at a specialized center, recovered well and left early.

This highlights the safety and effectiveness of multimodal therapy, especially when experts handle it.

Treating malignant pleural mesothelioma is tough. However, new surgical and therapy methods bring hope. Decortication, coupled with heated intrathoracic chemo, is promising.

Multimodal therapy, combining surgery, chemo, and radiation, improves survival and lowers the risk of relapse. As research and treatments advance, these methods will better mesothelioma outcomes.

Source:

Quiroga, Nestor Ivan, Leandro Ezequiel Grando, Xavier Michavila Oller, Pablo Luis Paglialunga, Ángela Guirao Montes, and David Sanchez-Lorente. “Malignant Pleural Mesothelioma: Description of Pleural Decortication and Hyperthermic Chemotherapy Technique in Multimodal Therapy.” Multimedia Manual of Cardiothoracic Surgery: MMCTS 2024 (May 15, 2024). https://doi.org/10.1510/mmcts.2024.007.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    ByAlex Strauss

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    New Approach to Decrease Mesothelioma Symptom

    ByAlex Strauss

    Draining off excess lung fluid with an indwelling catheter may be a better way to deal with this mesothelioma symptom than surgery, according to a new study. Pleural effusion, a build-up of fluid between the two layers of the lining around the lungs, is a common side effect of several cancers, including malignant pleural mesothelioma. Approximately half of all patients with metastatic cancer develop pleural effusion, which can have a dramatic impact on quality of life by inhibiting a person’s ability to breathe freely. Many mesothelioma patients also experience chest pain and fatigue as a result of pleural effusion. If untreated, pleural effusion can lead to pneumonia or lung collapse. Some mesothelioma patients with pleural effusion are treated with pleurodesis,…

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    ByAlex Strauss

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • | |

    Mesothelioma Report Suggests Clinical Trials Better Than Surgery

    ByAlex Strauss

    Doctors in the Department of Respiratory medicine at York Teaching Hospital in the UK are taking a hard stance against the surgical treatment of malignant pleural mesothelioma. In a recent article in the journal Thorax, the group contends that the research surrounding mesothelioma surgery is largely flawed and that the majority of mesothelioma patients would be better served if their doctors suggested alternatives. “Belief that the modest survival times reported after radical surgery, whether alone or as part of multimodal therapy, are longer than they would have been without surgery relies on data from highly selected, uncontrolled, retrospectively analyzed case series,” they write. They point out that the only randomized study, the Mesothelioma and Radical Surgery (MARS) trial showed no measurable…